Global Transarterial Chemoembolization (TACE) Market Size, Share, Forecast Report, 2020-2027

The global Transarterial Chemoembolization (TACE) market garnered revenue around USD XX Billion in 2019 and projected to reach USD 2 Billion in 2027, with at a compound annual growth rate of 8.60 % throughout the estimate period from 2020 to 2027.

The increasing prevalence of liver cancer is expected to drive the growth of the global transarterial chemoembolization (TACE) market. Hepatocellular carcinoma (HCC) is fifth cancer in terms of incidence and the second leading cause of cancer death for men worldwide. The incidence of HCC is highest in Asia and Africa.

Transarterial chemoembolization is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC. However, systemic toxicity induced by conventional TACE in some cases has led to the introduction of drug-eluting bead TACE.

Increasing incidence of HCC is strongly fueling the transarterial chemoembolization (TACE) market.

Increasing prevalence of hepatocellular carcinoma: HCC has an annual incidence of approximately 750,000 cases per year worldwide. Its incidence continues to increase due to the increasing incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections.

Dearth of skilled healthcare professionals

High costs of treatment

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Transarterial Chemoembolization (TACE) market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Transarterial Chemoembolization (TACE) market growth.

The global Transarterial Chemoembolization (TACE) market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

Advaxis Inc. (US)

Baxter (US)

Bellicum Pharmaceuticals, Inc. (US)

Boston Scientific Corporation (US)

Cook (US)

Hikma Pharmaceuticals PLC (UK)

Isofol Medical AB (Sweden)

Nippon Kayaku Co., Ltd. (Japan)

Novartis (Switzerland)

Pfizer (US)

Sirtex SIR-Spheres Pty Ltd. (Australia)

Spectrum Pharmaceuticals, Inc. (US)

Jiangsu Hengrui Medicine Co., Ltd. (China)

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

By Procedure Type

Conventional TACE

DEB-TACE:

By Indication



Unresectable HCC:

Early-Stage HCC:

By Product Type

Chemotherapeutic Agents:

Radiotherapeutic Agents:

Drug-eluting Particles:

By End-User

Hospitals & Clinics:

Cancer Research Centers:

Regional Analysis and Forecast



Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:



� North America

? U.S.

? Canada

� Europe

? Germany

? U.K.

? Italy

? France

? Rest of EU

� Asia Pacific

? China

? India

? Japan

? Southeast Asia

? Rest of APAC

� Central & South America

? Brazil

? Argentina

? Rest of Central & South America

� Middle East and Africa

? UAE

? Saudi Arabia

? Rest of MEA